Characterization of insulin-like growth factor binding protein-3 (IGFBP-3) binding to human breast cancer cells: kinetics of IGFBP-3 binding and identification of receptor binding domain on the IGFBP-3 molecule.

Insulin-like growth factor binding protein-3 (IGFBP-3) binds to specific membrane proteins located on human breast cancer cells, which may be responsible for mediating the IGF-independent growth inhibitory effects of IGFBP-3. In this study, we evaluated IGFBP-3 binding sites on breast cancer cell membranes by competitive binding studies with IGFBP-1 through -6 and various forms of IGFBP-3, including synthetic IGFBP-3 fragments. Scatchard analysis revealed the existence of high-affinity sites for IGFBP-3 in estrogen receptor-negative Hs578T human breast cancer cells (dissociation constant (Kd) = 8.19 +/- 0.97 x 10(-9) M and 4.92 +/- 1.51 x 10(5) binding sites/cell) and 30-fold fewer receptors in estrogen receptor-positive MCF-7 cells (Kd = 8.49 +/- 0.78 x 10(-9) M and 1.72 +/- 0.31 x 10(4) binding sites/cell), using a one-site model. These data demonstrate binding characteristics of typical receptor-ligand interactions, strongly suggesting an IGFBP-3:IGFBP-3 receptor interaction. Among IGFBPs, only IGFBP-5 showed weak competition, indicating that IGFBP-3 binding to breast cancer cell surfaces is specific and cannot be attributed to nonspecific interaction with glycosaminoglycans. This was confirmed by showing that synthetic IGFBP-3 peptides containing IGFBP-3 glycosaminoglycan-binding domains competed only weakly for IGFBP-3 binding to the cell surface. Rat IGFBP-3 was 20-fold less potent in its ability to compete with human IGFBP-3(Echerichia coli), as well as 10- to 20-fold less potent for cell growth inhibition than human IGFBP-3, suggesting the existence of species specificity in the interaction between IGFBP-3 and the IGFBP-3 receptor. When various IGFBP-3 fragments were evaluated for affinity for the IGFBP-3 receptor, only those fragments that contain the midregion of the IGFBP-3 molecule were able to inhibit 125I-IGFBP-3(Escherichia coli) binding, indicating that the midregion of the IGFBP-3 molecule is responsible for binding to its receptor. These observations demonstrate that specific, high-affinity IGFBP-3 receptors are located on breast cancer cell membranes. These receptors have properties that support the notion that they may mediate the IGF-independent inhibitory actions of IGFBP-3 in breast cancer cells.

[1]  R. Baxter,et al.  Structural Determinants of Ligand and Cell Surface Binding of Insulin-like Growth Factor-binding Protein-3* , 1998, The Journal of Biological Chemistry.

[2]  E. Wilson,et al.  Inhibition of Insulin Receptor Activation by Insulin-like Growth Factor Binding Proteins* , 1997, The Journal of Biological Chemistry.

[3]  S. Leal,et al.  The Type V Transforming Growth Factor β Receptor Is the Putative Insulin-like Growth Factor-binding Protein 3 Receptor* , 1997, The Journal of Biological Chemistry.

[4]  P. Cohen,et al.  Insulin-like Growth Factor (IGF)-binding Protein-3 Induces Apoptosis and Mediates the Effects of Transforming Growth Factor-β1 on Programmed Cell Death through a p53- and IGF-independent Mechanism* , 1997, The Journal of Biological Chemistry.

[5]  J. Weiler,et al.  Structure-function relationships in the heparin-binding C-terminal region of insulin-like growth factor binding protein-3. , 1996, Growth regulation.

[6]  J. Fowlkes,et al.  Characterization of Glycosaminoglycan-binding Domains Present in Insulin-like Growth Factor-binding Protein-3* , 1996, The Journal of Biological Chemistry.

[7]  R. Eckert,et al.  Retinoid X receptor-specific retinoids inhibit the ability of retinoic acid receptor-specific retinoids to increase the level of insulin-like growth factor binding protein-3 in human ectocervical epithelial cells. , 1996, Cancer research.

[8]  Z. Gucev,et al.  Insulin-like Growth Factor Binding Protein 3 Mediates Retinoic Acid- and Transforming Growth Factor β2-induced Growth Inhibition in Human Breast Cancer Cells , 1996 .

[9]  M. Pollak,et al.  Estradiol and Antiestrogens Regulate a Growth Inhibitory Insulin-like Growth Factor Binding Protein 3 Autocrine Loop in Human Breast Cancer Cells (*) , 1996, The Journal of Biological Chemistry.

[10]  Z. Gucev,et al.  Insulin-like growth factor binding protein 3 mediates retinoic acid- and transforming growth factor beta2-induced growth inhibition in human breast cancer cells. , 1996, Cancer research.

[11]  D. Andress.  Heparin Modulates the Binding of Insulin-like Growth Factor (IGF) Binding Protein-5 to a Membrane Protein in Osteoblastic Cells (*) , 1995, The Journal of Biological Chemistry.

[12]  J. Fowlkes,et al.  Insulin-like Growth Factor (IGF)-binding Protein-3 (IGFBP-3) Functions as an IGF-reversible Inhibitor of IGFBP-4 Proteolysis (*) , 1995, The Journal of Biological Chemistry.

[13]  S. Velasco-Miguel,et al.  Induction of the growth inhibitor IGF-binding protein 3 by p53 , 1995, Nature.

[14]  R. Rosenfeld,et al.  Transforming Growth Factor- β-induced Cell Growth Inhibition in Human Breast Cancer Cells Is Mediated through Insulin-like Growth Factor-binding Protein-3 Action (*) , 1995, The Journal of Biological Chemistry.

[15]  P. Cohen,et al.  The human insulin-like growth factor (IGF) binding protein-3 inhibits the growth of fibroblasts with a targeted disruption of the IGF-I receptor gene. , 1995, Molecular endocrinology.

[16]  J. Weiler,et al.  IGFBP-3 and IGFBP-5 association with endothelial cells: role of C-terminal heparin binding domain. , 1995, Growth regulation.

[17]  F. May,et al.  Estrogen regulated messenger RNAs in human breast cancer cells. , 1995, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[18]  Z. Gucev,et al.  Antiproliferative actions of insulin-like growth factor binding protein (IGFBP)-3 in human breast cancer cells. , 1995, Progress in growth factor research.

[19]  K. Suzuki,et al.  Matrix metalloproteinases degrade insulin-like growth factor-binding protein-3 in dermal fibroblast cultures. , 1994, The Journal of biological chemistry.

[20]  D. Clemmons,et al.  Heparin, heparan sulfate, and dermatan sulfate regulate formation of the insulin-like growth factor-I and insulin-like growth factor-binding protein complexes. , 1994, The Journal of biological chemistry.

[21]  S. Chernausek,et al.  Insulin-like growth factor-binding protein-3 (IGFBP-3) concentration in rat Sertoli cell-conditioned medium is regulated by a pathway involving association of IGFBP-3 with cell surface proteoglycans. , 1994, Endocrinology.

[22]  R. Rosenfeld,et al.  Demonstration of receptors for insulin-like growth factor binding protein-3 on Hs578T human breast cancer cells. , 1993, The Journal of biological chemistry.

[23]  D. Clemmons,et al.  Insulin-like growth factor binding protein 1 stimulates cell migration and binds to the alpha 5 beta 1 integrin by means of its Arg-Gly-Asp sequence. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[24]  R. Rosenfeld,et al.  Insulin-like growth factor (IGF)-independent action of IGF-binding protein-3 in Hs578T human breast cancer cells. Cell surface binding and growth inhibition. , 1993, The Journal of biological chemistry.

[25]  Y. Anraku,et al.  Structure of the heme-copper binuclear center of the cytochrome bo complex of Escherichia coli: EPR and Fourier transform infrared spectroscopic studies. , 1993, Biochemistry.

[26]  W. McGuire,et al.  Expression of insulin‐like growth factor binding proteins in human breast cancer correlates with estrogen receptor status , 1993, Journal of cellular biochemistry.

[27]  T. Okajima,et al.  Transfection of the human insulin-like growth factor binding protein-3 gene into Balb/c fibroblasts inhibits cellular growth. , 1993, Molecular endocrinology.

[28]  U. Eppenberger,et al.  Inhibition of growth‐factor‐activated proliferation by anti‐estrogens and effects on early gene expression of mcf‐7 cells , 1993, International journal of cancer.

[29]  M. Rechler.  Insulin-like growth factor binding proteins. , 1993, Vitamins and hormones.

[30]  R. Baxter,et al.  Insulin-like growth factor-I (IGF-I) and transforming growth factor-beta 1 release IGF-binding protein-3 from human fibroblasts by different mechanisms. , 1992, Endocrinology.

[31]  R. Gennis,et al.  Modified, large-scale purification of the cytochrome o complex (bo-type oxidase) of Escherichia coli yields a two heme/one copper terminal oxidase with high specific activity. , 1992, Biochemistry.

[32]  C. Conover,et al.  Potentiation of insulin-like growth factor (IGF) action by IGF-binding protein-3: studies of underlying mechanism. , 1992, Endocrinology.

[33]  Darrell M. Wilson,et al.  Effects of insulin-like growth factors (IGFs) and IGF receptor antibodies on the proliferation of human breast cancer cells. , 1992, Growth factors.

[34]  P. Campbell,et al.  Insulin‐Like growth factor binding protein (IGFBP) inhibits igf action on human osteosarcoma cells , 1991, Journal of cellular physiology.

[35]  H. Rochefort.  Mechanism of Action of High‐Affinity Antiestrogens An Overview , 1991, American journal of clinical oncology.

[36]  N. Rosen,et al.  Growth factor messenger RNA expression by human breast fibroblasts from benign and malignant lesions. , 1991, Cancer research.

[37]  C. Blat,et al.  Presence of IDF45 (mlGFBP-3) binding sites on chick embryo fibroblasts. , 1991, Biochemical and biophysical research communications.

[38]  J. Culouscou,et al.  Purification of a colon cancer cell growth inhibitor and its identification as an insulin-like growth factor binding protein. , 1991, Cancer research.

[39]  D. Leroith,et al.  Retinoid modulation of insulin-like growth factor-binding proteins and inhibition of breast carcinoma proliferation. , 1991, Endocrinology.

[40]  C. Blat,et al.  IGFBP-1, an insulin like growth factor binding protein, is a cell growth inhibitor. , 1991, Biochemical and biophysical research communications.

[41]  C. Osborne,et al.  Insulin-like growth factor binding protein secretion by breast carcinoma cell lines: correlation with estrogen receptor status. , 1990, Endocrinology.

[42]  D. Powell,et al.  Characterization of insulin-like growth factor-binding proteins in human serum from patients with chronic renal failure. , 1990, The Journal of clinical endocrinology and metabolism.

[43]  A. Herington,et al.  Cloning and characterization of the growth hormone-dependent insulin-like growth factor binding protein (IGFBP-3) in the rat. , 1990, Biochemical and biophysical research communications.

[44]  J. Flynn,et al.  Cloning and expression of human insulin-like growth factor binding protein 3. , 1990, Growth factors.

[45]  C. Osborne,et al.  Insulin-like growth factor-II (IGF-II): a potential autocrine/paracrine growth factor for human breast cancer acting via the IGF-I receptor. , 1989, Molecular endocrinology.

[46]  M. Ranke,et al.  Insulin-like growth factor I (IGF-I)-binding protein complex is a better mitogen than free IGF-I. , 1989, Endocrinology.

[47]  A. Puustinen,et al.  Cytochrome o (bo) is a proton pump in Paracoccus denitrificans and Escherichia coli , 1989, FEBS letters.

[48]  R. Baxter,et al.  Growth hormone-dependent insulin-like growth factor (IGF) binding protein both inhibits and potentiates IGF-I-stimulated DNA synthesis in human skin fibroblasts. , 1988, Biochemical and biophysical research communications.

[49]  R. Voutilainen,et al.  Insulin-like growth factor (IGF) binding protein from human decidua inhibits the binding and biological action of IGF-I in cultured choriocarcinoma cells. , 1988, Endocrinology.

[50]  R. Derynck,et al.  Evidence that transforming growth factor-β is a hormonally regulated negative growth factor in human breast cancer cells , 1987, Cell.

[51]  D. Kaufman,et al.  Secretion of an insulin-like growth factor-I-related protein by human breast cancer cells. , 1986, Cancer research.

[52]  Y. Anraku,et al.  Assignment of ESR signals of Escherichia coli terminal oxidase complexes. , 1985, Biochimica et biophysica acta.

[53]  Y. Anraku,et al.  Resonance Raman study of cytochrome b562-o complex, a terminal oxidase of Escherichia coli in its ferric, ferrous, and CO-ligated states. , 1985, The Journal of biological chemistry.

[54]  R. Furlanetto,et al.  Somatomedin-C receptors and growth effects in human breast cells maintained in long-term tissue culture. , 1984, Cancer research.

[55]  Y. Anraku,et al.  Terminal oxidases of Escherichia coli aerobic respiratory chain. I. Purification and properties of cytochrome b562-o complex from cells in the early exponential phase of aerobic growth. , 1984, The Journal of biological chemistry.

[56]  R. Sutherland,et al.  HIGH MOLECULAR WEIGHT SOMATOMEDIN-C/IGF-I FROM T47D HUMAN MAMMARY CARCINOMA CELLS: IMMUNOREACTIVITY AND BIOACTIVITY , 1983 .

[57]  D Rodbard,et al.  Ligand: a versatile computerized approach for characterization of ligand-binding systems. , 1980, Analytical biochemistry.